Glenmark Pharma
and its biotech subsidiary,
Ichnos Sciences
announced the launch of their
alliance
–
Ichnos Glenmark Innovation
(IGI) – to accelerate new
drug discovery
in cancer treatment. This alliance combines Glenmark’s research and development proficiencies in small molecules with those of Ichnos in novel biologics to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors, says a company statement.
The newly formed IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors currently undergoing clinical trials.
Two of these molecules have received orphan drug designation from the USFDA. Additionally IGI has two autoimmune disease assets that have been out-licensed to leading companies.
English (US) ·